Heart Failure
Bernard Brain and Harold Heart
Learn about the signs and symptoms of heart failure
Search
270 Result(s)
Heart Failure
Living with heart failure – Patricia’s story
Hear Patricia’s story on the impact that heart failure can have on mental health and the importance of building support networks.
Heart Failure
Understanding heart failure
Learn more about heart failure including its burden, symptoms, different types and association to other conditions.
Heart Failure
Guide to living with heart failure
Find out Harold’s tips on living with this condition
Heart Failure
Heart Failure in Women
Gain knowledge on how gender disparities appear in heart failure care. You’ll hear from global experts on how women can be supported through their journey and empowered to manage their care, from diagnosis to disease management.
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
July 30, 2020
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
August 27, 2021
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
July 06, 2021
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
June 21, 2021
Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
December 13, 2019
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure
Corporate Profile
Heart disease and treatments can be similar in humans and animals. How?
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well. Watch and learn how
Article
Connect with your Heart
Asking the right questions can help a loved one in your family
January 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
May 21, 2021
Positive CHMP opinion for a heart failure indication
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
June 28, 2021
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
Pets
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Pets
Do you know how to protect your pet from heartworm disease?
Have you heard about heartworms before? These dangerous parasites can infest your cat or dog through mosquito bites, causing serious illness. Sounds scary? It doesn´t have to be!
September 09, 2021
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
November 17, 2019
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
June 06, 2022
Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
Animal Health Innovation
Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions